Association of Gastric Acid Suppression and Sorafenib Efficacy in Advanced Hepatocellular Carcinoma
Authors:
- 9 June 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 55 (2) , 169-173
Abstract
Background: Recent studies have revealed that coadministration of gastric acid suppressants reduces the efficacy of the tyrosine kinase inhibitors erlotinib and sunitinib in patients with non–small cell lung cancer and renal cell carcinoma, respectively. The authors have therefore assessed if the concurrent use of gastric acid suppressants and sorafenib impairs outcomes in patients with advanced hepatocellular carcinoma (HCC). Methods: A retrospective analysis was conducted on all patients treated with sorafenib for advanced HCC at a single tertiary referral unit in the United Kingdom, between January 2008 and January 2014. A multivariate Cox proportional hazard model was used to assess the effect of the concomitant use of gastric acid suppression and sorafenib on progression-free survival (PFS) and overall survival (OS). Results: Data were collected from 197 patients, of which 182 could be assessed for this study; 77 (42%) were on concurrent gastric acid suppression therapy. After adjusting for imbalances between the groups, a Cox regression analysis gave an adjusted hazard ratio for the concurrent acid suppression group compared with the no acid suppression group of 5.4 (95% confidence interval, 3.6-7.9) for PFS and 1.85 (95% confidence interval, 1.3-2.6) for OS. Conclusions: This single-center experience shows that patients with advanced HCC taking sorafenib and concomitant gastric acid suppression therapy have significantly inferior PFS and OS. This is the first time that this negative interaction has been reported and further prospective validation is warranted.Keywords
This publication has 23 references indexed in Scilit:
- A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung CancerClinical Cancer Research, 2010
- Proton pump inhibitors: actions and reactionsDrug Discovery Today, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Sorafenib for the Treatment of Advanced Renal Cell CarcinomaClinical Cancer Research, 2006
- Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumorsAnnals of Oncology, 2005
- Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid TumorsJournal of Clinical Oncology, 2005
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- Enterohepatic CirculationClinical Pharmacokinetics, 2002
- Drug Interactions with Proton Pump InhibitorsDrug Safety, 1997
- Pharmacokinetic and Pharmacodynamic Properties of Histamine H2-Receptor AntagonistsClinical Pharmacokinetics, 1991